Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b

Journal of Molecular Biology

Volumn 402, Issue 1, 2010, Pages 17-29

  Garcia, Brandon L ^a   Ramyar, Kasra X ^a   Tzekou, Apostolia ^b   Ricklin, Daniel ^b   McWhorter, William J ^a   Lambris, John D ^b   Geisbrecht, Brian V ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

C3 convertase; Complement; Complement inhibitor; Immune evasion; Staphylococcus aureus

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; STAPHYLOCOCCAL COMPLEMENT INHIBITOR; UNCLASSIFIED DRUG; PROTEIN BINDING;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY; CHEMISTRY; HUMAN; IMMUNOLOGY; METABOLISM; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS AUREUS;

BINDING SITES; COMPLEMENT C3B; COMPLEMENT C3C; COMPLEMENT INACTIVATOR PROTEINS; CRYSTALLOGRAPHY, X-RAY; HUMANS; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS;

EID: 77956180132     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.07.029     Document Type: Article

References (44)

1. Lambris J.D., Sahu A., Wetsel R. The chemistry and biology of C3, C4, and C5. The Human Complement System in Health and Disease 1998, Marcel Dekker, Inc., New York, NY. J.E. Volanakis, M. Frank (Eds.).
2. Morikis D., Lambris J.D. Structural Biology of the Complement System 2005, Taylor & Francis, Boca Raton, FL. D. Morikis, J.D. Lambris (Eds.).
3. Wetsel R.A., Kildsgaard J., Haviland D.L. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. Therapeutic Interventions in the Complement System 2000, Humana Press, Totowa, NJ. J.D. Lambris, V.M. Holers (Eds.).
4. Janssen B.J.C., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes underlying complement activity. Nature 2006, 444:213-216.
5. Janssen B.J.C., Huizinga E.G., Raaijmakers H.C.A., Roos A., Daha M.R., Ekdahl-Nilsson K., et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
6. Gros P., Milder F.J., Janssen B.J.C. Complement driven by conformational changes. Nat. Rev., Immunol. 2008, 8:48-58.
7. Thurman J.M., Holers V.M. The central role of the alternative complement pathway in human disease. J. Immunol. 2006, 176:1305-1310.
8. Pangburn M.K., Muller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the biomolecular proteinase. Biochem. J. 1986, 235:723-730.
9. Sahu A., Lambris J.D. Structure and biology of complement protein 3, a connecting link between innate and acquired immunity. Immunol. Rev. 2001, 180:35-48.
10. Mollnes T.E., Song W.C., Lambris J.D. Complement in inflammatory tissue damage and disease. Trends Immunol. 2002, 23:61-64.
11. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 2007, 25:1265-1275.
12. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520-532.
13. Foster T.J. Immune evasion by Staphylococci. Nat. Rev., Microbiol. 2005, 3:948-958.
14. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev., Microbiol. 2008, 6:132-142.
15. Geisbrecht B.V. Staphylococcal complement inhibitors: biological functions, recognition of complement components, and potential therapeutic implications. Adv. Exp. Med. Biol. 2008, 632:221-236.
16. Rooijakkers S.H.M., Milder F.J., Bardoel B.W., Ruyken M., van Strijp J.A.G., Gros P. Staphylococcal complement inhibitor: structure and active sites. J. Immunol. 2007, 179:2989-2998.
17. Rooijakkers S.H., Ruyken M., Roos A., Daha M.R., Presanis J.S., Sim R.B., et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005, 6:920-927.
18. Jongerius I., Köhl J., Pandey M.K., Ruyken M., van Kessel K.P., van Strijp J.A., Rooijakkers S.H. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 2007, 204:2461-2471.
19. Ricklin D., Tzekou A., Garcia B.L., Hammel M., McWhorter W.J., Sfyroera G., et al. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 2009, 183:2565-2574.
20. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009, 10:721-727.
21. Garcia B.L., Tzekou A., Ramyar K.X., McWhorter W.J., Ricklin D., Lambris J.D., Geisbrecht B.V. Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2009, 65:482-485.
22. Lambris J.D., Ross G.D. Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres. J. Immunol. 1982, 128:186-189.
23. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
24. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
25. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60:2126-2132.
26. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58:1948-1954.
27. Zwart P.H., Afonine P.V., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., et al. Automated structure solution with the PHENIX suite. Methods Mol. Biol. 2008, 426:419-435.
28. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
29. Russell R.B., Barton G.J. Multiple protein sequence alignment from tertiary structure comparison: assignment of global and residue confidence levels. Proteins 1992, 14:309-323.
30. Janssen B.J., Halff E.F., Lambris J.D., Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 2007, 282:29241-29247.
31. Hammel M., Sfyroera G., Ricklin D., Magotti P., Lambris J.D., Geisbrecht B.V. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 2007, 8:430-437.
32. Hammel M., Sfyroera G., Pyrpassopoulos S., Ricklin D., Ramyar K.X., Pop M., et al. Characterization of Ehp: a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 2007, 202:30051-30061.
33. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007, 372:774-797.
34. Jongerius I., Puister M., Wu J., Ruyken M., van Strijp J.A., Rooijakkers S.H. Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases. J. Immunol. 2010, 184:420-425.
35. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006, 444:217-220.
36. Wu J., Wu Y.Q., Ricklin D., Janssen B.J., Lambris J.D., Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 2009, 10:728-733.
37. Rooijakkers S.H., van Kessel K.P., van Strijp J.A. Staphylococcal innate immune evasion. Trends Microbiol. 2005, 13:596-601.
38. Janssen B.J., Gomes L., Koning R.I., Svergun D.I., Koster A.J., Fritzinger D.C., et al. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J. 2009, 28:2469-2478.
39. Harboe M., Ulvund G., Vien L., Fung M., Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 2004, 138:439-446.
40. Chavakis T., Wiechmann K., Preissner K.T., Herrmann M. Staphylococcus aureus interactions with the endothelium: the role of bacterial "secreteable expanded repertoire adhesive molecules" (SERAM) in disturbing host defense systems. Thromb. Haemostasis 2005, 94:278-285.
41. Palma M., Wade D., Flock M., Flock J.I. Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen. J. Biol. Chem. 1998, 273:13177-13181.
42. Lee L.Y.L., Liang X., Hook M., Brown E.L. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J. Biol. Chem. 2004, 279:50710-50716.
43. Ricklin D., Ricklin-Lichtsteiner S.K., Markiewski M.M., Geisbrecht B.V., Lambris J.D. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J. Immunol. 2008, 181:7463-7467.
44. Mollnes T.E. Therapeutic manipulation of the complement system. The Complement System: Novel Roles in Health and Disease 2004, Kluwer Academic Publishers, Boston, MA. J. Szebeni (Ed.).